Modified patient stem cells as prelude to autologous treatment of muscular dystrophy.
Duchenne muscular dystrophy is a devastating muscle wasting disease for which there is no effective treatment. In this issue of Cell Stem Cell, Benchaouir et al. (2007) demonstrate the delivery of genetically corrected CD133+ patient cells into mice, suggesting a new potential avenue for autologous cell therapy.
Davies
Kay E
KE
MRC Functional Genetics Unit, University of Oxford, Oxford OX1 3QX, UK. kay.davies@dpag.ox.ac.uk
Grounds
Miranda D
MD
D000071916:AC133 Antigen; D000818:Animals; D015703:Antigens, CD / Q000235:genetics; D004195:Disease Models, Animal; D006023:Glycoproteins / Q000235:genetics; D006801:Humans; D051379:Mice; D009136:Muscular Dystrophies / Q000628:therapy*; D010455:Peptides / Q000235:genetics; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000502:physiology*; D014161:Transduction, Genetic; D014182:Transplantation, Autologous; D014183:Transplantation, Heterologous
D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; C000606024:Prom1 protein, mouse